- Neil Daly
- When we invested
- Series A
- Digital health
What we do
We enable GPs to conduct dermatologist quality skin cancer assessments within seconds whilst reducing their referral volumes.
For Hospitals, we’re able to design new pathways that are 40% more efficient and reduce demand on the scarce dermatology resource.
We build innovative skin cancer pathways that leverage our clinically validated AI to diagnose more skin cancer
- Clinically validated AI both for efficacy and health economic benefit.
- Regulatory clearance in Europe and FDA Breakthrough Device designation.
- Proven in the real world with NHS and private health providers.